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INTRODUCTION
Primary systemic therapy (PST) for breast cancer was ini-
tially used in cases of locally advanced inoperable disease in 
order to achieve surgical resection [1]. The use of PST was ex-
tended to operable breast cancer regardless of axillary status 
based on results showing that disease-free and overall survival 
obtained with adjuvant chemotherapy improved and more pa-
tients were able to receive breast-conserving surgery [2,3].
Sentinel lymph node biopsy (SLNB) has been accepted as an 
accurate and safe alternative to axillary lymph node dissection 
(ALND) for early breast cancer, and is associated with negligi-
ble morbidity compared with ALND [4-6]. However, SLNB is 
not recommended for axillary staging after PST because of low 
detection rates in several retrospective, single-institution stud-
ies [7,8]. However, a recent meta-analysis and prospective mul-
ticenter study suggested the feasibility of SLNB after PST by 
showing that the detection rate and false-negative (FN) rate 
were similar to those reported for early-stage breast cancer with-
out PST [9,10]. The results of the National Surgical Adjuvant 
Breast and Bowel Project B27 have also shown that there are 
no significant differences in the detection rate and FN rate of 
SLNB after PST according to clinical nodal status [11].
PST has been shown to downstage up to 40% of pre-PST doc-
umented axillary lymph node (ALN) metastases and to eradi-
cate biopsy-proven ALN metastases in 32% of patients [12-14]. 
Although axillary downstaging has been observed after PST, 
standard surgical treatment after PST consists of primary breast 
tumor resection and level I-II ALND. SLNB is performed prior 
to PST to achieve more accurate nodal staging. This strategy may 
neglect the fact that patients with complete tumor response in 
metastatic axillary lymph nodes could be spared from undergo-
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Purpose: Primary systemic therapy (PST) downstages up to 40% 
of initial documented axillary lymph node (ALN) metastases in 
breast cancer. The current surgical treatment after PST consists 
of breast tumor resection and axillary lymph node dissection 
(ALND). This strategy, however, does not eliminate unnecessary 
ALND in patients with complete remission of axillary metastases. 
The aim of this study was to examine the accuracy of sentinel 
lymph node biopsy (SLNB) after PST among patients with docu-
mented ALN metastasis at presentation and to identify the rate of 
pathologic complete-remission (CR) with ALN after PST. Methods: 
We analyzed 66 patients with ALN metastasis that was pathol- 
ogically proven preoperatively who underwent SLNB and con-
comitant ALND after PST. Axillary ultrasound (AUS) was used to 
evaluate the clinical response of initially documented ALN me-
tastasis after PST. Intraoperative lymphatic mapping was per-
formed using blue dye with or without radioisotope. Results: After 
PST, 34.8% of patients had clinical CR of ALN on AUS and 28.8% 
patients had pathologic CR of ALN. The overall success rate of 
SLNB after PST was 87.9%, and the sentinel lymph node identi-
fication rate in patients with clinical CR was 95.7%. In patients 
with successful lymphatic mapping, 70.7% of patients had resid-
ual axillary metastases. The overall accuracy and false-negative 
rate were 87.9% and 17.1% in all patients: 95.5% and 10.0% in 
patients with clinical CR of ALN, and 83.3% and 19.4% in patients 
with residual axillary disease after PST. Conclusion: Our findings 
suggest that SLNB may be feasible in patients with initial docu-
mented ALN metastasis who have clinical CR for metastatic ALN 
after PST. Further investigation in a prospective setting should be 
performed to confirm our results.
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ing ALND. Therefore, it is important to ascertain whether SLNB 
after PST can accurately identify patients for whom ALND can 
be avoided. 
The objective of this study was two-fold. First, we examined 
the accuracy of SLNB after PST among patients with breast cancer 
who had pathologically proven ALD metastases at the initial 
diagnosis. Second, we identified the rates of clinical and patho-
logic complete remission (CR) in the ALN after PST. In addi-
tion, we compared the differences in SLNB accuracy accord-
ing to clinically axillary response after PST.
METHODS
From August 2003 to June 2009, 169 patients with breast 
cancer who underwent surgical treatment after PST at Seoul 
National University Bundang Hospital were retrospectively iden-
tified from the hospital’s surgical database. All patients were 
free of distant metastases and had T1 through T4, N0 through 
N3 breast cancer at the time of initial diagnosis. SLNB and con-
comitant ALND were performed prospectively for 89 patients 
after PST. Among these patients, fine-needle aspiration cytol-
ogy (FNAC) was performed in 70 patients with clinically sus-
picious ALNs on ultrasonographic findings. Sixty-six patients 
presented with pathologically proven ALN metastases, and these 
patients constituted the present study sample. This retrospec-
tive study was approved by our Institutional Review Board.
At our institute, patients undergo axillary ultrasound (AUS) 
for initial axillary staging at presentation as well as clinical re-
sponse in axilla after PST. Initial AUS findings and follow-up 
AUS imaging after PST were reviewed by a single radiologist 
with specific expertise in breast imaging at our institution. Sus-
picion of AUS was based on the presence of an asymmetric, 
hypoechoic prominence of the cortex or loss of fatty hilum. 
FNAC of suspicious lymph nodes was performed by a radiol-
ogist using ultrasound guidance to target the abnormal areas 
of the nodes. All patients diagnosed with axillary metastases 
underwent AUS to evaluate the clinical response in breast and 
ALNs after PST. We divided patients into two groups according 
to clinical axillary response using ultrasound findings as fol-
lows: normal and fatty replaced lymph nodes on axillary ul-
trasound were classified as clinical CR, and suspicion of resid-
ual disease was classified as clinical non-CR. Dissected ALNs 
were evaluated for pathologic tumor response in axillary me-
tastases. Patients who had no metastatic carcinoma in the dis-
sected nodes were considered to have had a pathologic CR for 
metastatic ALNs. Pathologic CR for primary breast tumor was 
considered to indicate no invasive cancer. Estrogen and proges-
terone receptors were scored as percentage of cells which stain 
with the antibody. Until May 2010, the cancer was classified as 
hormone receptor positive in our institution if there were at 
least 10% positive tumor nuclei in the sample on testing in the 
presence of expected reactivity of internal (normal epithelial 
elements) and external controls. Comparisons of post-PST AUS 
findings and final pathology of ALNs were performed to assess 
whether ultrasound could predict complete tumor response in 
the axilla. 
Intraoperative lymphatic mapping was performed using blue 
dye with or without radioisotope. Periareolar injection of 99mTc-
labeled antimony sulfur colloid (Seoul National University Bun-
dang Hospital, Seongnam, Korea) was performed 1-3 hours 
before the operation, and 5 mL of 0.8% indigocarmine (Korea 
United Pharm Inc., Seoul, Korea) was injected intraoperative-
ly. All sentinel lymph nodes (SLNs) were examined intraoper-
atively by serial sectioning and hematoxylin and eosin staining. 
Additional immunohistochemical labeling for cytokeratin was 
performed to further evaluate the status of SLNs on permanent 
section. All patients underwent concomitant ALND after SLNB.
The success rate of SLNB was defined as the number of pa-
tients whose SLN was isolated in relation to the total number 
of patients in this study. FN rate was defined as the ratio of the 
number of patients with a FN case of SLNB to the number of 
patients with at least one involved SLN or non-SLN. Compari-
sons of the success and FN rates according to clinical response 
after PST were performed using Fisher’s exact tests, and p< 
0.05 was considered statistically significant.
RESULTS
Table 1 shows the clinicopathologic characteristics of the 66 
patients. The average clinical tumor size of 45 patients (68.2%) 
was between 2 cm and 5 cm, and 13 patients (19.7%) had a large 
tumor (>5 cm) at the time of diagnosis. Prior to surgery, 35 
patients (53.0%) were treated with four cycles of a combination 
of doxorubicin (60 mg/m
2) and cyclophosphamide (600 mg/m
2), 
and 28 patients (42.4%) received three or six cycles of a combi-
nation of docetaxel (75 mg/m
2) and doxorubicin (50 mg/m
2). 
One patient was treated with three cycles of a combination of 
docetaxel (75 mg/m
2) and epirubicin (100 mg/m
2), and two 
patients with six cycles of a combination of paclitaxel (175 mg/ 
m
2), gemcitabine (1,200 mg/m
2), and trastuzumab (4 mg/kg). 
Twenty-eight patients (42.4%) underwent a total mastectomy 
for their primary tumors, and 38 patients (57.6%) underwent 
breast conserving surgery. Fourteen patients (21.2%) had com-
plete pathologic response in the primary breast tumor after PST.
On initial AUS findings, the most common characteristics of 
abnormal lymph nodes were uneven cortical thickening (47.0%) 
and round hypoechoic mass (45.5%). Enlarged lymph nodes 
were spread throughout level I only (71.0%), level I and II (25.8 SLNBafterPSTinBreastCancerPatientswithPositive-Node 149
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%), and level I, II and III (1.5%). The mean number of enlarged 
lymph nodes was 3.0 (range, 1-10). After PST, 43 patients had 
clinically residual nodal disease and 23 patients had a clinical 
CR in axilla on ultrasound examination. Nineteen (28.8%) of 
the 66 patients with metastatic ALN showed pathologic CR of 
axillary metastases at the time of SLNB and completion of ALND. 
Six (14.0%) of 43 patients with clinical non-CR and 13 (52.2%) 
of 23 patients with clinical CR were found to have pathologic 
CR on final pathology. The AUS for evaluating the tumor re-
sponse in metastatic ALNs after PST had a sensitivity of 78.7%, 
a specificity of 68.4%, a positive predictive value of 86.0%, a 
negative predictive value of 52.2%, and an accuracy of 75.8% 
(Table 2). 
Lymphatic mapping was performed with both radioactive 
colloid and blue dye in 61 patients, and with blue dye alone in 
five patients. The mean number of SLNs removed was 2.8 (range, 
1-8), and the SLNs were located in the axilla in all patients. The 
mean number of nodes retrieved after completion of ALND 
was 19.9 (range, 5-44). The overall SLN identification rate after 
PST was 87.9% (58/66). According to clinical tumor response 
in the axilla, the identification rates of SLN between clinical CR 
and non-CR were 95.7% (22/23) and 83.7% (36/43), however, 
the difference was not statistically significant (p=0.244). In 58 
patients who had successful lymphatic mapping, 41 patients 
(70.7%) had pathologically residual axillary metastases. The 
pathologic status of the SLN and ALN in all patients is showed 
in Table 3. The SLN accurately predicted axillary nodal status 
in 51 of 58 patients (overall accuracy, 87.9%). Seven patients 
had FN findings, the overall FN rate of 17.1% (7/41). 
In the SLNB success group, 22 patients had clinical CR in the 
Table 1. Patient characteristics
Characteristics No. of patients %
Age (yr) 
   <50 
   ≥50 
 
38
28
 
57.6
42.4
Clinical tumor size (cm) 
   ≤2 
   >2, ≤5 
   >5 
 
  8
45
13
 
12.1
68.2
19.7
Type of PST 
   Doxorubicin+Cyclophosphamide 
   Docetaxel+Doxorubicin 
   Others 
 
35
28
  3
 
53.0
42.4
  4.5
Type of surgery, breast 
   Mastectomy 
   Breast conserving surgery 
 
28
38
 
42.4
57.6
Pathologic subtype 
   Ductal 
   Others 
 
63
  3
 
95.5
  4.5
Pathologic T stage 
   T0 
   Tis 
   T1 
   T2 
   T3 
  
  7
  7
32
19
  1
  
10.6
10.6
48.5
28.8
  1.5
Pathologic N stage 
   N0
   N1
   N2 
   N3 
  
19
26
13
  8
  
28.8
39.4
19.7
12.1
Hormonal receptor status 
   ER negative 
   ER positive
   PR negative 
   PR positive
  
28
38
43
23
  
42.4 
57.6
65.2
34.8
PST=primary systemic therapy; ER=estrogen receptor; PR=progeste­
rone receptor.
Table 2. Correlation of AUS findings after PST with surgical lymph node 
pathology
AUS findings
Pathologic axillary lymph node status
Total
Negative Positive
Clinical CR 13 10 23
Clinical non­CR   6 37 43
Total 19 47 66
Sensitivity, 78.7% (37/47); Specificity, 68.4% (13/19); Positive predictive 
value, 86.0% (37/43); Negative predictive value, 52.2% (13/23); Accu­
racy, 75.8% (50/66).
AUS=axillary ultrasound; PST=primary systemic therapy; CR=complete 
remission. 
Table 3. Pathologic status of SLN and ALN in all patients 
ALN status
Total
Positive Negative
SLN status
   Positive 34   0 34
   Negative   7 17 24
   Total 41 17 58
False­negative rate, 17.1% (7/41); Overall accuracy, 87.9% (51/58); Neg­
ative predictive value, 70.8% (17/24); Positive predictive value, 100% 
(34/34).
SLN=sentinel lymph node; ALN=axillary lymph node; CR=complete 
remission. 
Table 4. Pathologic status of SLN and ALN in patients with clinically re­
sidual nodal disease
Clinical non­CR group
ALN status
Total
Positive Negative
SLN status
   Positive 25 0 25
   Negative   6 5 11
   Total 31 5 36
False­negative rate, 19.4% (6/31); Overall accuracy, 83.3% (30/36); 
Negative predictive value, 45.5% (5/11); Positive predictive value, 100% 
(25/25).
SLN=sentinel lymph node; ALN=axillary lymph node; CR=complete 
remission. 150  EunyoungKang,etal.
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axilla, and 36 patients had abnormal appearance of the ALNs. 
Among patients with clinical non-CR, the SLN accurately pre-
dicted axillary nodal status in 30 of 36 patients (83.3%) and the 
FN rate was 19.4% (Table 4). In patients with clinical CR, the 
overall accuracy and FN rate were 95.5% and 10.0% (Table 5). 
However, there were no significant differences in FN rates ac-
cording to clinical tumor response in axilla (p=0.660). There 
were no significant differences in the success rates for SLNB 
and FN rate according to age, clinical and pathologic tumor 
size, type of PST, or hormonal receptor (data not shown).
DISCUSSION
In early breast cancer with clinically negative ALN, SLNB is 
an accurate predictor of the pathologic status of ALNs. How-
ever, some have speculated that the disease status of the SLN 
in patients who receive PST does not accurately reflect the dis-
ease status of entire axilla due to fibrosis of tumor lymphatics 
and the potential obstruction of lymphatics by cellular material 
or tumor emboli [15,16]. Therefore, it has been suggested that 
SLNB should be performed before PST. There are some disad-
vantages to this approach, because patients would have at least 
two operations and patients with nodal disease and evidence of 
nodal regression would not have the chance to avoid ALND, 
which is associated with morbidity. 
There have been many studies evaluating the feasibility of 
SLNB after PST, and identification rates of 72% to 100% and 
false negative rates of 0% to 33% have been reported [7,17-19]. 
According to meta-analyses of these studies, the estimated iden-
tification rate for SLNB after PST was 91% and the sensitivity 
of SLNB was 88%, with a FN rate of 12% [9]. These results sug-
gest that SLNB is a reliable technique for determining the need 
for ALND in clinically node-negative patients after PST. Pre-
viously, several studies of the feasibility of SLNB after PST in 
patients with cytologically documented positive lymph nodes 
at presentation were conducted. Among 793 patients from 19 
studies, the identification of SLN was 85%, in half of studies it 
was 90% or higher, and the FN rate was 11% [20]. These find-
ings suggest that SLNB after PST is reasonable in patients with 
positive node. 
In our study, the post-PST SLNB in patients with axillary 
metastases at presentation did not seem to be feasible, as there 
was a higher false negative rate of 17.1% than previous results 
from conventional lymphatic mapping in early breast cancer. 
Although there were no statistically significant differences be-
tween patients with clinically CR and patients with residual ad-
enopathy, we observed lower FN rates and higher identification 
rates of SLNB in patients with clinical CR (10%, 95.7%) than 
in patients with clinical non-CR (19.4%, 83.7%) for nodal dis-
ease after PST. These findings suggest that SLNB may be feasi-
ble in patients with imaging evidence of CR for their axillary 
disease after PST. 
PST has been shown to sterilize cytologically proven metastat-
ic ALNs in 23% to 32% of patients [12,13]. In our study, 28.8% 
of patients with axillary metastases at diagnosis had a patholog-
ically complete response, and ALND might not be necessary in 
such patients. Metastatic lymph node response to chemother-
apy is also important to provide prognostic information. Kuerer 
et al. [12] showed that complete remission of nodal metastases 
after PST was a strong predictor of disease-free survival (87% 
in patients with preoperative eradication of axillary metastases 
vs. 51% in patients with residual nodal disease after 5 years), 
and also that the 5-year disease-free survival rate in patients 
with occult nodal metastasis was not significantly different from 
that in patients without occult nodal metastasis (87% vs. 75%, 
respectively, after 5 years). Based on the results of The National 
Surgical Adjuvant Breast and Bowel Project B-04 trial, although 
40% of breast cancer patients with clinically negative nodes have 
pathologically positive nodes, no survival advantage is associ-
ated with removing occult positive nodes at the time of initial 
surgery [21]. These studies support the use of SLNB as an al-
ternative to ALND after PST. 
Ultrasound is the most easily-applicable imaging tool for clin-
ical staging of ALN status in patients with breast cancer [22]. 
AUS, possibly in combination with FNAC of suspicious nodes 
has been identified as a preoperative procedure for the selec-
tion of breast cancer patient suitable for SLNB [23,24]. Our di-
agnoses were determined by AUS examination and ultrasound-
guided FNAC of suspicious nodes. Therefore, we selected AUS 
as the follow-up modality for comparison. However, our abili-
ty to identify patients with clinically negative axilla after PST 
was suboptimal. Results of the present study suggest that AUS 
is not reliable enough to predict pathologic status of the axilla 
after PST, with a low specificity of 68.4% and a low negative 
predictive value 52.2%. Therefore, another imaging modality 
Table 5. Pathologic status of SLN and ALN in patients with clinical CR 
Clinical CR group
ALN status
Total
Positive Negative
SLN status
   Positive   9   0   9
   Negative   1 12 13
   Total 10 12 22
False­negative rate, 10.0% (1/10); Overall accuracy, 95.5% (21/22); 
Negative predictive value, 95.5% (12/13); Positive predictive value, 100% 
(9/9).
SLN=sentinel lymph node; ALN=axillary lymph node; CR=complete 
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with better sensitivity and specificity such as positron emission 
tomography (PET) should be combined with AUS to identify 
patients who have clinically negative axilla after PST and who 
are appropriate candidates for SLNB. Recently, Straver et al. [25] 
demonstrated that monitoring the response of ALNs with FDG 
PET/CT during the early course of preoperative chemother- 
apy is feasible, with a reported sensitivity of 97% and specifici-
ty of 100%.
The small sample size and single institution survey are limita-
tions of our study. However, most of the SLNB were performed 
using a combination of blue dye and radioisotope, and the sur-
geon analyzed all SLNs in the setting of planned completion of 
ALND. 
In summary, our study was designed to evaluate the feasibil-
ity and accuracy of SLNB after PST in patients with axillary 
metastases at diagnosis. Although the overall FN rate was high-
er than that of early breast cancer, the FN rate in patients with 
clinical CR of nodal disease to PST was 10%. It suggests that 
SLNB may be feasible in patients with clinically complete axil-
lary response following PST. If this result is confirmed in a large 
randomized trial, SLNB will be generally accepted as the stan-
dard method for axillary staging in this group. We suggest a 
new algorithm of surgical treatment for axillary staging after 
PST (Figure 1), and expect that some patients with clinical CR 
of nodal metastases may be able to avoid unnecessary ALND.  
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